DCRI Think Tanks Demonstrate What Is PossibleTackling today’s healthcare challenges requires collaboration from every stakeholder, including patients, academic investigators, site investigators, regulatory agencies, pharmaceutical and device industry leaders, payers, technology companies and more.
DCRI Think Tanks demonstrate what is possible when you bring smart people together to tackle the biggest challenges in clinical research. From cardiovascular diabetes to the Pediatric Rule to the Modern Data Monitoring Committee, these meetings are about creating pathways to useful, focused discussions across the healthcare continuum and then moving consensus to action.
Our mission—to address the most critical gaps in clinical research by convening leaders across the healthcare industry to map the way forward in designing, conducting, and implementing high-quality, evidence-based research.
- Review value-added implications for new technological advances that enhance clinical trial efficiency and streamline trial conduct
- Discuss the emerging perspectives of clinical trial stakeholders on technology infiltration
- Delineate innovative trial designs and options facilitated by technological advances and potential barriers to implementation of innovative trials
- Determine the optimal framework for regulatory oversight and partnerships needed to guide the role of technology in changing clinical research paradigms
October 3-4, 2018
Technology-Enabled Clinical Trials—Innovations in Trial Design and Conduct
The “Technology-Enabled Clinical Trials” think tank meeting convened by Duke Clinical Research Institute brought together diverse stakeholders and perspectives to address the emerging perspectives on the evolution of technological solutions that support clinical trials. At this meeting, our aim was to foster the collaborative partnerships needed to ensure the proper oversight and implementation of these technological advances that are positioned to accelerate the assessment of promising new therapies.
Contact Carolyn Moore Arias with questions.
DCRI Think Tanks Publications
Heart Failure Preserved Ejection Fraction
Meeting date: June 7-8, 2017
Advancing Care and Clinical Trials through Digital Health
Meeting date: December 5-6, 2016
Issues in Pediatric Cardiovascular Drug Development
Meeting date: September 8-9, 2016
Leveraging E.H.R. for Clinical Research Now!
Meeting date: February 18-19, 2016
DCRI Think Tanks is partnered with the CardioVascular Clinical Trialists Forum (CVCT)—a unique experts-only forum aimed at discussing important and timely CV trials and trial science issues (design, methodology, interpretation, approval and implementation). Their emphasis on interaction among highly knowledgeable global experts from multiple backgrounds, including academy, industry R&D, regulatory agencies, major journal editors, NHLBI, payers (CMS, HTA organizations) and patient representatives makes them a key DCRI Think Tanks contributor.
DCRI Think Tank faculty lead Dr.Matthew Roe and Fred Cobb Distinguished Professor of Medicine Dr.Eric Peterson will be chairing a joint CVCT-Duke Think Tank session with Dr. Martin Cowie at the upcoming annual 2018 CVCT meeting titled “eSolutions – Big Data – Smart Data and How These May Help with Clinical Evidence Generation” on Friday, November 30 at 2:00pm.
Patient-Reported Outcome Measures
Meeting date: July 25-26, 2018
Key questions addressed:
- What does it mean to justify the use of a PRO in a regulated trial?
- How comfortable are key stakeholders in tolerating different degrees of uncertainty about the validity of a PRO measure for different contexts of use?
- What types of studies are best suited to justify the use of PRO measures in different contexts?
Kevin Weinfurt, PhD
Professor and Vice Chair for Research
Department of Population Health Sciences
Duke University School of Medicine
Co-Director, Duke Center for Health Measurement
Cardiovascular Outcomes and Diabetes Drugs: Lessons Learned and Path Forward
DCRI faculty joined a DCRI Research Forum panel on March 6, 2018 to share their perspectives on Cardiovascular Outcomes and Diabetes Drugs after attending a think tank meeting on the same topic.